Dasatinib/HP-β-CD Inclusion Complex Based Aqueous Formulation as a Promising Tool for the Treatment of Paediatric Neuromuscular Disorders

New scientific findings have recently shown that dasatinib (DAS), the first-choice oral drug in the treatment of chronic myeloid leukemia (CML) for adult patients who are resistant or intolerant to imatinib, is also potentially useful in the paediatric age. Moreover, recent preclinical evidences sug...

Descripción completa

Detalles Bibliográficos
Autores principales: Cutrignelli, Annalisa, Sanarica, Francesca, Lopalco, Antonio, Lopedota, Angela, Laquintana, Valentino, Franco, Massimo, Boccanegra, Brigida, Mantuano, Paola, De Luca, Annamaria, Denora, Nunzio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6386909/
https://www.ncbi.nlm.nih.gov/pubmed/30704045
http://dx.doi.org/10.3390/ijms20030591

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6386909/
https://www.ncbi.nlm.nih.gov/pubmed/30704045
http://dx.doi.org/10.3390/ijms20030591

Ejemplares similares